• news.cision.com/
  • Attana/
  • Updated agenda for Stora Aktiedagen on December 1 at 10.30 now including review of new diagnostic data

Updated agenda for Stora Aktiedagen on December 1 at 10.30 now including review of new diagnostic data

Report this content

On Wednesday December 1 at 10.30, Attana will participate in Aktiespararna’s Stora Aktiedag where Attana’s CEO, Teodor Aastrup, will give a 20-minute-long presentation followed by a 10-minute-long Q&A.

The content of the presentation has been updated from the previously communicated agenda and will now also include a review of initial data generated from the study carried out by Attana in collaboration with the Linnaeus University and Region Kalmar.

In the ongoing study, patient samples are tested both before and after vaccination against different variants of the SARS-CoV-2 virus (Alpha and Delta). Preliminary observations from the initial studies, combined with the latest development of new SARS-CoV-2 variants, highlight the importance of new and more advanced diagnostic solutions.

As previously communicated, the event is live streamed and can be viewed on Aktiespararna’s Youtube channel. Listeners are welcome to send questions for Attana to the moderator via sms to 079 347 98 45 or by writing directly in the live chat.

When: Wednesday, December 1 at 10.30

Where: Live streamed from Hotel Sheraton, can be accessed through this link

For more information, please contact:

Teodor Aastrup, CEO
teodor.aastrup@attana.com
+46 (0)8 674 57 00

The Board of directors for Attana consider that the information in this press release is not likely to have a significant effect on the share price but is of general interest for the shareholders and hence should be communicated.

About Attana

Attana was founded in 2002 with the vision of in vitro characterization of molecular interactions mimicking in vivo conditions. Since then, Attana has developed proprietary label free biosensors for biochemical, crude, sera, and cell-based assays and the Attana Virus Analytics (AVA) platform, a proprietary in vitro diagnostics (IVD) tool. Attana products and research services are used by Big Pharma, biotech companies and academic institutions within the life sciences. To learn more about our latest services and products, please visit www.attana.com or contact sales@attana.com

Subscribe

Documents & Links